Sudden death due to atrial fibrillation in hypertrophic cardiomyopathy: A predictable event in a young patient

PACE - Pacing and Clinical Electrophysiology

Volumn 26, Issue 2 I, 2003, Pages 637-639

  Favale, Stefano ^a,c   Pappone, Carlo ^b   Nacci, Frida ^a   Fino, Francesco ^a   Resta, Francesco ^a   Dicandia, Cosimo D ^b  

^a UNIVERSITY OF BARI   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c NONE   (Italy)

Author keywords

Hypertrophic cardiomyopathy; Implantable cardioverter defibrillator; Sudden death; Ventricular fibrillation

Indexed keywords

AMIODARONE; VERAPAMIL;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; CONTROLLED STUDY; DEFIBRILLATOR; DISEASE COURSE; FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; FAMILY HISTORY; FEMALE; HEART ATRIUM FIBRILLATION; HEART ATRIUM PACING; HEART VENTRICLE FIBRILLATION; HUMAN; INCIDENCE; PREDICTION; SUDDEN DEATH; SUPRAVENTRICULAR TACHYCARDIA;

EID: 12444292236     PISSN: 01478389     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1460-9592.2003.00107.x     Document Type: Article

References (17)

1. Maron BJ, Hypertrophic cardiomyopathy. Lancet 1997; 350:127-33. [Erratum, Lancet 1997; 350:1330.]
2. Spirito P, Seidman CE, McKenna WJ, et al. The management of hypertrophic cardiomyopathy. N Engl J Med 1997; 336:775-785.
3. Sadoul N, Prasad K, Elliott PM, et al. Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation 1997; 96:2987-2991.
4. Olivotto I, Maron BJ, Montereggi A, et al. Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy. J Am Coll Cardiol 1999; 33:2044-2051.
5. Spirito P, Rapezzi C, Autore C, et al. Prognosis of asymptomatic patients with hypertrophic cardiomyopathy and non sustained ventricular tachycardia. Circulation 1994; 90:3743-3747.
6. McKenna WJ, Camm AJ. Sudden death in hypertrophic cardiomyopathy: Assessment of patients at high risk. Circulation 1989; 80:1489-1492.
7. Spirito P, Seidman CE, McKenna W, et al. The management of hypertrophic cardiomyopathy. N Engl J Med 1997; 336:775-785.
8. McKenna WJ, Oakley CM, Krikler DM, et al. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br Heart J 1985; 53:412-416.
9. Maron BJ, Shen WK, Link MS, et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 2000; 342:365-373.
10. Favale S, Di Biase M, Rizzo U, et al. Ventricular fibrillation induced by transesophageal atrial pacing in hypertrophic cardiomyopathy. Eur Heart J 1987; 8:912-916.
11. Shah PM, Adelman AG, Wigle ED, et al. The natural (and unnatural) history of hypertrophic cardiomyopathy. Circ Res 1974; 35(Suppl. II):179-195.
12. McKenna WJ, Deanfield JE. Hypertrophic cardiomyopathy: An important cause of sudden death. Arch Dis Child 1984; 59:971-975.
13. McKenna W, Deanfield J, Faruqui A, et al. Prognosis in hypertrophic cardiomyopathy: Role of age and clinical, electrocardiographic and hemodynamic features. Am J Cardiol 1981; 47:532-538.
14. Fiddler GI, Tajik AJ, Weidman WH, et al. Idiopathic hypertrophic subaortic stenosis in the young. Am J Cardiol 1978; 42:793-799.
15. Maron BJ, Henry WL, Clark CE, et al. Asymmetric septal hypertrophy in childhood. Circulation 1976; 53:9-19.
16. Maron BJ, Bonow RO, Cannon RO III, et al. Hypertrophic cardiomyopathy: Interrelations of clinical manifestations, pathophysiology and therapy. N Engl J Med 1987; 316:780-789.
17. Spirito P, Bellone P, Harris KM, et al. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000; 342:1778-1785.